` AEZS (Aeterna Zentaris Inc) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

AEZS
vs
S&P TSX Composite Index (Canada)

Over the past 12 months, AEZS has underperformed S&P TSX Composite Index (Canada), delivering a return of -16% compared to the S&P TSX Composite Index (Canada)'s 21% growth.

Stocks Performance
AEZS vs S&P TSX Composite Index (Canada)

Loading
AEZS
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com

Performance Gap
AEZS vs S&P TSX Composite Index (Canada)

Loading
AEZS
S&P TSX Composite Index (Canada)
Difference
www.alphaspread.com

Performance By Year
AEZS vs S&P TSX Composite Index (Canada)

Loading
AEZS
S&P TSX Composite Index (Canada)
Add Stock

Competitors Performance
Aeterna Zentaris Inc vs Peers

S&P TSX Composite Index (Canada)
AEZS
ABBV
AMGN
GILD
VRTX
Add Stock

Aeterna Zentaris Inc
Glance View

Market Cap
18.9m CAD
Industry
Biotechnology

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The company is headquartered in Montreal, Quebec and currently employs 17 full-time employees. The firm's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The firm is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The company is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The firm focuses on the commercialization of macimorelin in Asia and the rest of the world.

AEZS Intrinsic Value
1.68 CAD
Overvaluation 67%
Intrinsic Value
Price
Back to Top